Kornimate/medical-research-clean huggingface dataset:
drug provocation test (dpt) to paracetamol

Conditions: Drug Hypersensitivity

Summary: background : paracetamol (acetaminophen) drug hypersensitivity reactions (dhr) are oonfirmed in about 10% of alleged cases. the diagnosis is made via an empirical drug provocation test (dpt). objective: detect eliciting dose thresholds during paracetamol dpt in order to suggest optimal step doses and to identify variables and potential risk factors associated with paracetamol hypersensitivity. methods:this retrospective study, using the survival analysis and the multivariate analysis, will comprise all patients who attended the allergy service of the university hospital of montpellier from 1996 till 2018 with a clinical history related to paracetamol dhr, who underwent paracetamol dpt and who gave their consent to be included in the study. the patients are selected from the drug allergy \& hypersensitivity database (dahd).


Eligibility criteria:
inclusion criteria: - patients with a positive or negative dpt to paracetamol exclusion criteria: * patients refusing to take part in the study * patient under 10 years old

Keywords: drug hypersensitivity reaction drug provocation test paracetamol reactive doses reactive times acetaminophen
effect supplementation of coenzyme q10 in acute stemi underwent ppci

Conditions: ST Segment Elevation Myocardial Infarction (STEMI); Coenzyme Q10

Summary: left ventricular remodeling can still occur after primary percutaneous coronary intervention (pci). global longitudinal strain (gls) assessment has been used as a predictor of left ventricular remodeling. coenzyme q10 is known for its anti-inflammatory and antioxidant properties, which may help reduce cardiac remodeling. this study aims to determine the effect of coq10 administration after myocardial infarction as an adjunct to standard therapy on left ventricular remodeling, assessed through changes in gls values. researchers will compare coenzyme q10 to a placebo to see if coenzyme q10 has a greater effect on improving left ventricular gls values in patients with st-elevation myocardial infarction undergoing primary percutaneous coronary intervention.

this is a randomized, double blind study with 2 treatment groups. participants diagnosed with acute stemi post primary pci who meet the inclusion criteria and no exclusion criteria are given an explanation regarding the research and additional therapy that will be given, then informed consent is requested. participants will be randomized to one of the two treatment groups by chance. patients randomized to the first group will receive coenzyme q10 100mg/12hours. patients randomized to the other treatment group will receive a placebo. it is expected that the patients of the treatment group with the coenzyme q10 will have a greater improvement of their gls.

Eligibility criteria:
inclusion criteria: * age \> 21 - 80 years * agree to participate in the study * patients with a diagnosis of acute myocardial infarction with st-segment elevation (ami-ste) with onset \< 12 hours who underwent primary percutaneous coronary intervention (pci) * successful primary pci on the culprit lesion (residual stenosis \< 20%, timi flow iii) * received standard medication therapy according to guidelines (guideline-directed medical therapy; gdmt) achieved during hospitalization * sinus rhythm at the time of echocardiographic examination exclusion criteria: * patients who routinely consume coq10 prior to the study * patients with hemodynamic conditions of killip class iii-iv and nyha class iii-iv * patients with a history of previous acute myocardial infarction * patients with a history of previous pci or fibrinolytic therapy * patients with a history of previous coronary artery bypass surgery * patients with heart valve disease greater than moderate severity * patients receiving warfarin therapy * patients with a diagnosis of isolated right ventricular infarction * patients with inadequate echocardiographic image quality (poor echo window)

Keywords: coenzyme q10 acute myocardial infarction st segment elevation myocardial infarction (stemi) global longitudinal strain ubiquinone primary percutaneous coronary intervention cardiovascular disease
the accuracy of conventional versus digital implant impression techniques

Conditions: Missing Teeth

Summary: intraoral oral scanning significantly improves scanning accuracy compared to digitized conventional impression techniques. the digitized closed tray impression technique showed significantly more accurate results than the digitized open-tray impression technique in partially edentulous patients.

the study was a controlled clinical trial using cone-beam computed tomography (cbct) imaging and flapless surgical technique to place implants. cone-beam computed topography of the patients was taken by x-ray machine to create a dicom file of the patient. intraoral scanning to create stl files of the patient arches. each patient had undergone four impression techniques: conventional impression i; closed tray impression technique, conventional impression ii; splinted open tray impression technique, digital impression i; intraoral scanning of readymade abutments and digital impression ii; intraoral scanning using scan bodies. to digitize the conventional impressions i and ii, the readymade abutment was screwed on the analogs of the resultant stone casts, followed by digital scanning. using the scan body, the exact implant position was determined and the implants were added using a digital library. the custom abutment was fabricated on the implant replica with the same readymade abutment measurement. using the inspection software, a custom abutment was superimposed on each readymade abutment in all the readymade abutment scanning data with the best-fit algorithm. then the custom abutment was saved as a new stl file for comparison. the digital impression i was set as a reference in all the coming comparisons. the comparison was done from different data acquisition techniques by using inspection software between digital impression i, digital impression ii; and finally, with the digitized stl of the conventional impressions i and ii.

Eligibility criteria:
inclusion criteria: * partial edentulous patients * sufficient bone volume to insert implants * age ranging from 30-50. * good oral hygiene. * intact hard and soft tissues, including treated teeth decay and healed teeth extraction socket exclusion criteria: * • completely edentulous patients * patients with bruxism or clinching * need for bone augmentation, * uncompensated diabetes mellitus, * immunocompromised status, radio- and/or chemotherapy * previous treatment with oral and/or intravenous aminobisphosphonates. * undergoing orthodontic treatment; * patients with metal crowns and any other metal materials on teeth * patients with soft tissue lesions and postoperative scars on the palate
vaginal and oral microbiome crosstalk

Conditions: Healthy; Vaginal Discharge

Summary: to study the vaginal and oral microbiome by swab samples. on selected cases, also papa smear will be studied.

to study the vaginal and oral microbiome by swab samples and on selected groups, by papa smear test, to find out the constitution of normal and vaginal microbiome and the cross-talk between oral and vaginal mucosa. to find out about the impact of human papilloma virus on the microbiome and vice versa.

Eligibility criteria:
inclusion criteria: * patients coming to turku university hospital dermato-venereology or gynaecology departments or to family planning clinics in the wellbeing services county of southwest finland for previously mentioned reasons exclusion criteria: * those not meeting the criteria
neoadjuvant rapamycin in patients undergoing radical cystectomy

Conditions: Invasive Bladder Cancer Stage II

Summary: this study aims to evaluate the effects of rapamycin directly on bladder tumors and the effects of rapamycin on the immune system of patients with bladder cancer.

this is a presurgical clinical trial which aims to understand the biologic activity of torc1 inhibition and safety in patients with bladder cancer. in this presurgical setting, paired pmbcs and tumor tissue is evaluated before and after exposure to rapamycin to address target specificity, drug delivery, physiologic effects on tumor growth and apoptosis, and correlation of biomarkers with clinical activity.

Eligibility criteria:
inclusion criteria: 1. have invasive (≥t1) bladder cancer 2. eastern cooperative oncology group (ecog) performance status of 0 or 1 3. in their treating physician's opinion is a good candidate for radical cystectomy 4. in their treating physician's opinion does not need neoadjuvant chemotherapy prior to cystectomy 5. be able to give informed consent 6. be age 18 or older 7. have adequate marrow function (defined as granulocytes greater than 1,500 cells/mm3 hemoglobin \>9.5 gm/dl or platelets more than 100,000 cells/mm3). 8. have adequate end-organ function (gfr \>30, bilirubin \<1.5, sgot \< 3x uln) 9. have a life expectancy \> one year 10. not have a prior history of non-bladder cancer unless the cancer is clinically stable and not requiring active treatment 11. not have received chemotherapy or radiotherapy in the prior 30 days exclusion criteria: 1. immunosuppressed state (e.g. hiv, use of chronic steroids) 2. fixed disease (clinical t4) 3. active, uncontrolled infections 4. hepatic impairment (sgot \>3x uln) 5. unhealed wounds 6. patients at risk of pregnancy who are unwilling or unable to take effective contraception before rapamycin therapy, during therapy, and for 12 weeks after discontinuation of therapy.

Keywords: bladder cancer cystectomy rapamycin
evaluation of pk and biomarkers after udca administrations to subjects who are overweight and have liver problems

Conditions: Overweight; Abnormal Liver Function Tests

Summary: a clinical study to evaluate pharmacokinetics, metabolomics and biomarker in subjects who are overweight and have liver problems after ursodeoxycholic acid multiple administration

this study has a randomized, open-label, three-treatment, one-sequence, placebo-controlled, multiple drug administration design. the purpose of this study is as follows; to evaluate pharmacokinetics, metabolomics and biomarker in subjects who are overweight and have liver problems after ursodeoxycholic acid administration

Eligibility criteria:
inclusion criteria: * healthy subjects aged 18 - 50 years * a body mass index (bmi) in the range of 25.0 kg/m2 - 30.0 kg/m2. * a alanine aminotransferase (alt) in the range of 40 - 200 iu/l * good health based on complete medical history, physical examinations, vital signs, electrocardiography (ecg), and clinical laboratory evaluations. exclusion criteria: * subjects who have clinically significant disease of cardiovascular, respiratory, renal, endocrinological, hematological, gastrointestinal, neurological(central nervous system), psychiatric disorders or malignant tumor * subject judged not eligible for study participation by investigator
online cognitive behavioral therapy targeting cardiac anxiety

Conditions: Online CBT Targeting Cardiac Anxiety

Summary: the purpose of the present study is to evaluate an internet-delivered exposure-based cognitive behavioral therapy (cbt) protocol tailored for patients following myocardial infaction (mi) to increase quality of life (qol) and physical activity by reducing cardiac anxiety.

in the present research project, the investigators have tailored a cbt protocol to target the hypothesized mechanisms of how cardiac anxiety affects the clinical course of mi; by using exposure therapy to reduce fear, hypervigilance, and misinterpretations of cardiac symptoms to reduce mi-related avoidance and increasing physical activity. participants (estimated n=100) are randomized to internet-delivered cbt for 8 weeks or to a waitlist offered treatment as usual. patients in the control arm will be crossed over to cbt treatment 3 months after the experimental group has completed treatment. assessments will be conducted pre-treatment, post-treatment, 3 months (primary endpoint), 1-, 2 - and 5 years after treatment. these measurement points will also include the control group as it is crossed over to cbt after the 3-month follow-up

Eligibility criteria:
inclusion criteria: * inclusion criteria: * myocardial infarction ≥ 6 months before assessment (type 1 stemi/nstemi) * age 18-80 years; * clinically significant cardiac anxiety that leads to severe distress and/or interferes with daily life * on adequate medical treatment(21); (e) able to read and write in swedish. exclusion criteria: * heart failure with severe systolic dysfunction (ejection fraction ≤ 35%) * significant valvular disease * planned coronary artery bypass surgery or percutaneous interventions * any medical restriction to physical exercise * severe medical illness * grade 3 hypertension (i.e., blood pressure ≥ 180 systolic and/or 110 diastolic) * severe psychiatric disorder or risk of suicide * alcohol dependency * ongoing psychological treatment.

Keywords: myocardial infarction cardiac anxiety internet-cbt secondary prevention
effect of age on treatment decision-making in elderly patients with acute myeloid leukemia

Conditions: Acute Myeloid Leukemia

Summary: patients aged ≥70 years with acute myeloid leukemia (aml) have a poorer prognosis than those aged 60 to 69 years. the poor outcome is the result of treatment-related toxicity in elderly patients, owing to comorbidities, the greater possibility of other hematopoietic disorders, and a biologically poor risk prognosis. anthracycline- and cytarabine-based therapy, administered for 3 and 7 days respectively (3 +7), remains the standard induction therapy for this patient population. this approach improved survival compared with supportive care (median, 5 vs. 3 months) for adults aged ≥ 65 years. however, the overall view has been that the results of intensive chemotherapy in elderly patients remain poor. although complete remission (cr) rates of 40% to 80% can be achieved in highly selected populations, long-term survival has been poor. furthermore, most clinical trials have only enrolled patients with an adequate performance status (ps). prognostic models have been developed from clinical trial data to predict the outcomes for older patients. however; each model relies on chronologic age. age is a surrogate measure for both changes in tumor biology and patient characteristics. understanding which patients are likely to benefit from intensive therapies versus low-intensity therapies or supportive care is critical. the definition of "fit" to undergo intensive induction therapy has not been established, and the therapeutic choice is mainly determined by physician and patient decision. in older patients, low-dose cytarabine (ld-arac) has been demonstrated to be more beneficial than best supportive care and hydroxyurea. the recent availability of new drugs that could have an improved side effect profile and, in some cases, bioavailability might offer future improvement for this patient population. in this setting, the investigators have tended to consider, since 2007, patients aged ≥70 years as potential candidates for alternative lower intensity therapy (ld-arac, hypomethylating agents) even when they presented in good physical condition. the investigators goal was to determine whether age ≥ 70 years could represent a useful and simple cut off for treatment decision-making in clinical practice and whether low-intensity therapy could be an alternative therapeutic approach to intensive chemotherapy even for patients aged ≥ 70 years who were theoretically "fit" (who /ecog/ ps of ≤ 2).


Eligibility criteria:
inclusion criteria: * are at least 70 years of age * have a diagnosis of aml according to world health organization (who) classification * provide signed, written informed consent exclusion criteria: * patients with acute promyelocytic leukemia * have an ecog score ≥2

Keywords: acute myeloid leukemia chemotherapy low-intensity therapy older patients prognosis supportive care
development of horse-riding program model for children with cerebral palsy

Conditions: Cerebral Palsy; Motor Activity

Summary: the purpose of this study is to develop healing riding algorithm applicable in rural riding centers and to apply this to children with cerebral palsy.

horseback riding activities in korea's riding centers have mostly centered on physical rehabilitation for children with special needs, including those with cerebral palsy, mental disabilities, and autism, with the program conducted by certified equine-assisted therapy instructors. however, there is no definite way to assess the ability of children for horseback riding and no standard riding program. therefore, developing a assessment and program algorithm for healing horseback riding is expected to contribute to providing more activities for children with special needs and also for general people. children older than 4 years old or adolescent with cerebral palsy who voluntarily want to enroll this study would be enrolled. participants have 2 times of 30-minute horse riding program for 8 weeks, total 16 times of riding program in a local horse riding center. sample size assessment: calculating for 20% of drop out, 16 patients were calculated to apply the assessment and applicable program. drop out: missing more than 2 lessons of horse-riding plan for missing data: not included statistical analysis plan: paired t-test for the outcome measures

Eligibility criteria:
inclusion criteria: * children or adolescent with cerebral palsy * gmfcs level i, ii, iii * body weight less than 80 kg exclusion criteria: * medical condition who are not suitable for hippotherapy: severe osteoporosis, mental illness, not controlled seizure disorder etc. * social condition who are not suitable for hippotherapy

Keywords: cerebral palsy horseback riding
initiative in lyon for lung cancer screening development - prevalence study

Conditions: Lung Cancer; Screening

Summary: screening at-risk subjects with low-dose computed tomography (ct) efficiently reduces lung cancer specific mortality. however screening efficiency relies on the at-risk population's criteria definition and its participation rate to the screening. in france, there are concerns regarding the participation rates to national cancer screening that are quite low (around 50% and 32% of the eligible population for breast cancer and colorectal cancer respectively). before organizing national lung cancer screening it is then crucial to determine the factors impacting the at-risk subjects willingness to participate in lung cancer screening. the lyon university hospital is the second biggest hospital in france with more than 23,000 employees distributed among more than 160 professions representing every level of education or working conditions. its population is heterogeneous and wide enough to perform a prevalence study assessing the willingness to participate among the at-risk population. ilyad is a prospective study performed by anonymous questionnaires that will be submitted to the 23,000 employees of the lyon university hospital. the study main objective is to evaluate the at-risk population presence in the lyon university hospital population, as defined by nelson criteria and selection criteria for lung cancer screening (plcom2012 scoring), and its willingness to participate to a lung-cancer screening with low-dose ct. this might help further efficient national lung cancer screening campaign organization.


Eligibility criteria:
inclusion criteria: * aged ≥ 18 years old * employee from the lyon university hospital (receiving salary from the lyon university hospital) * person who has willingness to respond the survey exclusion criteria: * employees not hired by the lyon university hospital * employees who have not willingness to participate in the survey
image guided intensity modulated reirradiation (ig-imrt) with cetuximab for locoregionally confined recurrent head and neck squamous cell carcinoma

Conditions: Squamous Cell Cancer of the Head and Neck

Summary: the standard treatment for head and neck cancer relapses in previously irradiated patients is controversial. reirradiation has had some success, but many patients still die from their disease. cetuximab is helpful in relapsed head and neck cancer, and it improves the effectiveness of radiation in some head and neck cancer patients. but, it has not been studied with reirradiation. the purpose of this study is to see the effects, both good and bad, of reirradiation with cetuximab.


Eligibility criteria:
inclusion criteria: * patients must have a pathologically confirmed recurrence (reappearance of previously cleared) squamous cell cancer in the upper aerodigestive tract or a second squamous cell primary. patients may have experienced more than one recurrence as long as the first recurrence occurred ≥6 months following the end of the prior rt. * the recurrence or second primary must be confined to the head and neck above the clavicles (loco-regional recurrence). * the majority (≥75%) of the tumor volume must have been in areas previously irradiated to ≥45 gy. the previous irradiation must not exceed a maximum of 75 gy. * patients must be at least 6 months from prior radiation therapy. * if a resection is performed after the diagnosis of recurrence and before enrollment, either microscopic or macroscopic disease must be present (i.e. positive margins or gross residual). * karnofsky performance status 60-100. * granulocytes ≥ 1500/mm3, platelets ≥ 100,000/mm3, bilirubin ≤ 1.5 mg/dl, creatinine ≤ 1.5 mg/dl, within 6 weeks prior to registration. * must be able to submit previous radiation records (simulation and portal film if available) in order to assure that cord tolerance is not exceeded. * patients must sign a study-specific informed consent form prior to study entry. * the patient must be between the ages of 18 and 75. exclusion criteria: * distant metastases. * completely resected recurrence with negative margins. * other concurrent invasive malignancies. * prior invasive malignancy unless disease free for at least two years (prior in situ malignancies are permissible). * intercurrent medical illnesses which would impair patient tolerance to therapy or limit survival. * pregnant and nursing women are excluded because of the potential teratogenic effects and potential unknown effects on nursing newborns. * previous treatment with cetuximab.

Keywords: squamous cell carcinoma, head and neck cancer